A water-based ink includes a pigment, and water, in which a viscosity at 20° C. is in a range of 2 mPa.Math.s to 7 mPa.Math.s, and a yield value at 20° C. is less than 0.2 mPa, and the yield value at 20° C. when evaporating 25% of the water is less than 0.8 mPa.

The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their preparation and therapeutic use in treating and/or preventing various diseases or disorders. The compounds and pharmaceutical compositions of the invention can be utilized to treat various diseases or disorders, such as diabetes, diabetic complications, dyslipidemia, hyperlipidemia, obesity, metabolic syndromes, pre-diabetes, atherosclerosis, heart diseases, neurodegenerative diseases, sarcopenia, muscle atrophy, inflammation, cancer and liver diseases and conditions such as fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cholestatic liver diseases or graft-versus-host disease of the liver. The compounds of this invention are also useful in improving liver functions in chronic viral associated liver diseases and alcohol-related liver diseases.

The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.

The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.

A metal oxide nanoparticle comprises a metal oxide core of formula M.sub.2O.sub.5, wherein M is tantalum (V) or niobium (V) and alkylsiloxane ligands bonded to the metal oxide core. The alkylsiloxane ligands are selected from the group consisting of isobutylsiloxane, allylsiloxane, vinylsiloxane, n-propyl siloxane, n-butylsiloxane, sec-butyl siloxane, tert-butyl siloxane, phenylsiloxane, n-octylsiloxane, isooctylsiloxane n-dodecyl siloxane, 4 -(trimethyl silyl)phenylsiloxane, para-tolylsiloxane, 4-fluorophenyl siloxane, 4 -chlorophenyl siloxane, 4-bromophenyl siloxane, 4-iodophenylsiloxane, 4-cyanophenyl siloxane, benzylsiloxane, methylsiloxane, ethylsiloxane, 4-(trifluoromethyl)phenylsiloxane, 4 -ammoniumbutylsiloxane, and any combination thereof.

A metal oxide nanoparticle comprises a metal oxide core of formula M.sub.2O.sub.5, wherein M is tantalum (V) or niobium (V) and alkylsiloxane ligands bonded to the metal oxide core. The alkylsiloxane ligands are selected from the group consisting of isobutylsiloxane, allylsiloxane, vinylsiloxane, n-propyl siloxane, n-butylsiloxane, sec-butyl siloxane, tert-butyl siloxane, phenylsiloxane, n-octylsiloxane, isooctylsiloxane n-dodecyl siloxane, 4 -(trimethyl silyl)phenylsiloxane, para-tolylsiloxane, 4-fluorophenyl siloxane, 4 -chlorophenyl siloxane, 4-bromophenyl siloxane, 4-iodophenylsiloxane, 4-cyanophenyl siloxane, benzylsiloxane, methylsiloxane, ethylsiloxane, 4-(trifluoromethyl)phenylsiloxane, 4 -ammoniumbutylsiloxane, and any combination thereof.

There is disclosed a compound Formula I ##STR00001##
In Formula I: Z is CR.sup.4R.sup.5, C═CR.sup.4R.sup.5, SiR.sup.4R.sup.5, GeR.sup.4R.sup.5, NR.sup.4a, PR.sup.4a, P(O)R.sup.4a, O, S, SO, SO.sub.2, Se; SeO, SeO.sub.2, Te, TeO, or TeO.sub.2; R.sup.1-R.sup.3 are the same or different at each occurrence and are D, aryl, heteroaryl, alkyl, amino, silyl, germyl, deuterated aryl, deuterated heteroaryl, deuterated alkyl, deuterated amino, deuterated silyl, or deuterated germyl, where two groups selected from R.sup.1, R.sup.2, and R.sup.3 can be joined together to form a fused ring; R.sup.4-R.sup.5 are the same or different at each occurrence and are H, D, aryl, heteroaryl, alkyl, amino, silyl, germyl, deuterated aryl, deuterated heteroaryl, deuterated alkyl, deuterated amino, deuterated silyl, or deuterated germyl; R.sup.4ais alkyl, silyl, germyl, aryl, or a deuterated analog thereof; a is an integer from 0-4; b and c are the same or different and are an integer from 0-3.

There is disclosed a compound Formula I ##STR00001##
In Formula I: Z is CR.sup.4R.sup.5, C═CR.sup.4R.sup.5, SiR.sup.4R.sup.5, GeR.sup.4R.sup.5, NR.sup.4a, PR.sup.4a, P(O)R.sup.4a, O, S, SO, SO.sub.2, Se; SeO, SeO.sub.2, Te, TeO, or TeO.sub.2; R.sup.1-R.sup.3 are the same or different at each occurrence and are D, aryl, heteroaryl, alkyl, amino, silyl, germyl, deuterated aryl, deuterated heteroaryl, deuterated alkyl, deuterated amino, deuterated silyl, or deuterated germyl, where two groups selected from R.sup.1, R.sup.2, and R.sup.3 can be joined together to form a fused ring; R.sup.4-R.sup.5 are the same or different at each occurrence and are H, D, aryl, heteroaryl, alkyl, amino, silyl, germyl, deuterated aryl, deuterated heteroaryl, deuterated alkyl, deuterated amino, deuterated silyl, or deuterated germyl; R.sup.4ais alkyl, silyl, germyl, aryl, or a deuterated analog thereof; a is an integer from 0-4; b and c are the same or different and are an integer from 0-3.

A compound, an organic light-emitting device, and a display apparatus, the compound being represented by Formula 1:

##STR00001##

A compound, an organic light-emitting device, and a display apparatus, the compound being represented by Formula 1:

##STR00001##